FI955319A0 - 2-pyridyylimetyleenipolyatsamakrosyklofosfonihappoja, niiden komplekseja ja johdannaisia käytettäväksi vasta-aineina - Google Patents
2-pyridyylimetyleenipolyatsamakrosyklofosfonihappoja, niiden komplekseja ja johdannaisia käytettäväksi vasta-aineinaInfo
- Publication number
- FI955319A0 FI955319A0 FI955319A FI955319A FI955319A0 FI 955319 A0 FI955319 A0 FI 955319A0 FI 955319 A FI955319 A FI 955319A FI 955319 A FI955319 A FI 955319A FI 955319 A0 FI955319 A0 FI 955319A0
- Authority
- FI
- Finland
- Prior art keywords
- complexes
- pyridylmethylenepolyazamacrocyclophosphonic
- derivatives
- antibodies
- acids
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 150000007513 acids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002872 contrast media Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/281—Means for the use of in vitro contrast agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/057,588 US5462725A (en) | 1993-05-06 | 1993-05-06 | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| PCT/US1994/005009 WO1994026275A1 (en) | 1993-05-06 | 1994-05-05 | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI955319A0 true FI955319A0 (fi) | 1995-11-06 |
| FI955319A FI955319A (fi) | 1995-12-22 |
Family
ID=22011534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI955319A FI955319A (fi) | 1993-05-06 | 1995-11-06 | 2-pyridyylimetyleenipolyatsamakrosyklofosfonihappoja, niiden komplekseja ja johdannaisia käytettäväksi vasta-aineina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5462725A (fi) |
| EP (1) | EP0711300B1 (fi) |
| JP (1) | JPH08510245A (fi) |
| CN (1) | CN1125905A (fi) |
| AT (1) | ATE227297T1 (fi) |
| AU (1) | AU678583B2 (fi) |
| BG (1) | BG100192A (fi) |
| CA (1) | CA2162174A1 (fi) |
| CZ (1) | CZ289595A3 (fi) |
| DE (1) | DE69431660T2 (fi) |
| FI (1) | FI955319A (fi) |
| HU (1) | HUT74565A (fi) |
| LV (1) | LV11430B (fi) |
| NO (1) | NO301829B1 (fi) |
| PL (1) | PL311643A1 (fi) |
| SG (1) | SG46458A1 (fi) |
| WO (1) | WO1994026275A1 (fi) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409689A (en) * | 1993-08-13 | 1995-04-25 | Concat, Ltd. | MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms |
| DE19523891C1 (de) * | 1995-06-30 | 1996-11-21 | Hoechst Ag | Chirale Mangan-triazanonankomplexe und Verfahren zu ihrer Herstellung |
| US5928627A (en) * | 1996-04-19 | 1999-07-27 | The Dow Chemical Company | Fluorescent chelates as visual tissue specific imaging agents |
| CA2382057A1 (en) * | 1999-09-13 | 2001-03-22 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
| US6685914B1 (en) | 1999-09-13 | 2004-02-03 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
| EP1362861B1 (en) * | 1999-09-13 | 2005-12-14 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
| EP1429783A4 (en) * | 2001-09-04 | 2006-08-09 | Univ Texas Tech | MULTIMODAL IMAGING CHELATES FOR MULTIPLE USES |
| US6962690B2 (en) | 2001-10-22 | 2005-11-08 | Dow Global Technologies Inc. | Tissue specific fluorescent chelates possessing long wavelength UV excitation |
| AU2003234576A1 (en) * | 2002-05-17 | 2003-12-02 | Case Western Reserve University | Chemical shift markers for improved wireless fiducial marker tracking |
| EP1778699A4 (en) * | 2004-08-10 | 2009-02-25 | Dow Global Technologies Inc | TARGETING OF CHELANTS AND CHELATES |
| EP1637524A1 (en) * | 2004-09-20 | 2006-03-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | 10-substituted 1-, 4, 7,-tris (carboxymethyl)-1,4,7,10-tetraazacyclo-dodecane derivative for use as contrast agents |
| PL1791565T3 (pl) | 2004-09-23 | 2016-10-31 | Modyfikowane cysteiną przeciwciała i koniugaty | |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP1805188A4 (en) * | 2004-09-30 | 2010-03-03 | Mds Analytical Technologies Us | COMPLEXES OF LUMINESCENT LANTHANIDES |
| SG172656A1 (en) | 2006-05-30 | 2011-07-28 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
| DK2845866T3 (en) | 2006-10-27 | 2017-07-10 | Genentech Inc | Antibodies and immunoconjugates and their applications |
| US7834154B2 (en) | 2007-02-09 | 2010-11-16 | Genentech, Inc. | Anti-ROBO4 antibodies and uses therefor |
| CN101802013B (zh) | 2007-07-16 | 2014-07-02 | 健泰科生物技术公司 | 人源化抗cd79b抗体和免疫偶联物及使用方法 |
| DK2176296T3 (da) | 2007-07-16 | 2012-05-21 | Genentech Inc | Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder. |
| MX351557B (es) | 2008-01-31 | 2017-10-19 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso. |
| US8499251B2 (en) | 2009-01-07 | 2013-07-30 | Microsoft Corporation | Virtual page turn |
| AU2010236787A1 (en) | 2009-04-01 | 2011-11-10 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
| ES2643446T3 (es) | 2009-06-04 | 2017-11-22 | Novartis Ag | Métodos para la identificación de sitios para conjugación de IgG |
| EP3778917A3 (en) | 2009-12-04 | 2021-06-09 | F. Hoffmann-La Roche AG | Multispecific antibodies, antibody analogs, compositions, and methods |
| WO2011153346A1 (en) | 2010-06-03 | 2011-12-08 | Genentech, Inc. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
| MX336540B (es) | 2010-06-08 | 2016-01-22 | Genentech Inc | Conjugados y anticuerpos manipulados geneticamente con cisteina. |
| KR20150030755A (ko) | 2012-07-04 | 2015-03-20 | 에프. 호프만-라 로슈 아게 | 항-바이오틴 항체 및 사용 방법 |
| JP6148729B2 (ja) | 2012-07-04 | 2017-06-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 共有結合している抗原−抗体結合体 |
| CN104394886B (zh) | 2012-07-04 | 2017-05-24 | 弗·哈夫曼-拉罗切有限公司 | 抗茶碱抗体及使用方法 |
| KR102278979B1 (ko) | 2014-01-03 | 2021-07-19 | 에프. 호프만-라 로슈 아게 | 공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도 |
| CA2933384A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| BR112016014945A2 (pt) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugado, formulação farmacêutica e uso |
| CA2957354A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| CN107001447B (zh) | 2014-12-17 | 2021-07-23 | 豪夫迈·罗氏有限公司 | 采用分选酶的酶介导多肽缀合新方法 |
| CN108138204B (zh) | 2015-09-25 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 使用分选酶a生产硫酯的方法 |
| WO2017050866A1 (en) | 2015-09-25 | 2017-03-30 | F. Hoffmann-La Roche Ag | Novel soluble sortase a |
| BR112018003594A2 (pt) | 2015-09-25 | 2018-09-25 | Hoffmann La Roche | cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados |
| EP3353314A1 (en) | 2015-09-25 | 2018-08-01 | H. Hoffnabb-La Roche Ag | Transamidation employing sortase a in deep eutectic solvents |
| WO2017167712A1 (en) | 2016-03-30 | 2017-10-05 | F. Hoffmann-La Roche Ag | Improved sortase |
| CN110709523B (zh) | 2017-04-12 | 2023-07-11 | 豪夫迈·罗氏有限公司 | 使用经pictet spengler反应获得的加标签的核苷的测序反应方法 |
| WO2019012019A1 (en) | 2017-07-13 | 2019-01-17 | F. Hoffmann-La Roche Ag | NEW BINDING AGENT AND DOSAGE FOR PIVKA |
| BR112020007321A2 (pt) | 2017-10-20 | 2020-09-29 | F. Hoffmann-La Roche Ag | conjugado de anticorpo, uso, uso de um marcador isotópico estável e kit |
| WO2019108755A1 (en) | 2017-11-30 | 2019-06-06 | Genentech, Inc. | Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1 |
| EP3492460A1 (en) * | 2017-12-01 | 2019-06-05 | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. | Compounds for separation of rare earth elements, method of separation, and use thereof |
| BR112020018235A2 (pt) | 2018-03-14 | 2020-12-29 | F. Hoffmann-La Roche Ag | Métodos para gerar uma biblioteca de polinucleotídeos, bibliotecas de polinucleotídeos, uso de uma biblioteca, método para gerar uma biblioteca de anticorpos e método de seleção de um anticorpo |
| BR112020017941A2 (pt) | 2018-03-14 | 2021-02-17 | F. Hoffmann-La Roche Ag | anticorpos, moléculas de ácido nucleico, vetor, composição e método de determinação da troponina t cardíaca humana |
| CN111936522A (zh) | 2018-04-18 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 新型抗胸苷激酶抗体 |
| EP3844503B1 (en) | 2018-08-31 | 2024-05-29 | F. Hoffmann-La Roche AG | Thymidine kinase (tk-1) in prognostic indices for dlbcl |
| WO2020069433A1 (en) | 2018-09-28 | 2020-04-02 | Imaginab, Inc. | Cd8 imaging constructs and methods of use thereof |
| WO2021013786A1 (en) | 2019-07-22 | 2021-01-28 | F. Hoffmann-La Roche Ag | S100a6 as blood biomarker for the non-invasive diagnosis of endometriosis |
| BR112022001140A2 (pt) | 2019-07-22 | 2022-03-15 | Hoffmann La Roche | Métodos para avaliar se um paciente tem endometriose ou está em risco de desenvolver endometriose, selecionar um paciente para terapia e monitorar um paciente que sofre de endometriose ou que está sendo tratado para endometriose |
| WO2021013781A1 (en) | 2019-07-22 | 2021-01-28 | F. Hoffmann-La Roche Ag | Substance p as blood biomarker for the non-invasive diagnosis of endometriosis |
| WO2021013785A1 (en) | 2019-07-22 | 2021-01-28 | F. Hoffmann-La Roche Ag | S100a9 as blood biomarker for the non-invasive diagnosis of endometriosis |
| BR112022000945A2 (pt) | 2019-07-22 | 2022-03-08 | Hoffmann La Roche | Métodos para avaliar se uma paciente tem endometriose ou está em risco de desenvolver endometriose, para selecionar uma paciente para terapia e para monitorar uma paciente que sofre de endometriose ou que está sendo tratada para endometriose |
| CN114728984A (zh) | 2019-11-15 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于患者样品中质谱测量的β-内酰胺类抗生素的衍生化 |
| EP4237855A1 (en) | 2020-10-30 | 2023-09-06 | F. Hoffmann-La Roche AG | Timp1 as a marker for cholangiocarcinoma |
| EP4237441A1 (en) | 2020-11-02 | 2023-09-06 | F. Hoffmann-La Roche AG | Sars-cov-2 nucleocapsid antibodies |
| WO2022207628A1 (en) | 2021-03-30 | 2022-10-06 | F. Hoffmann-La Roche Ag | Scf as blood biomarker for the non-invasive diagnosis of endometriosis |
| EP4314838A1 (en) | 2021-04-01 | 2024-02-07 | F. Hoffmann-La Roche AG | Psp94 as blood biomarker for the non-invasive diagnosis of endometriosis |
| WO2022243210A1 (en) | 2021-05-17 | 2022-11-24 | F. Hoffmann-La Roche Ag | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS |
| WO2023072904A1 (en) | 2021-10-26 | 2023-05-04 | F. Hoffmann-La Roche Ag | Monoclonal antibodies specific for sars-cov-2 rbd |
| WO2023111168A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | A novel antibody for detection of amyloid beta 42 (aβ42) |
| WO2023131594A1 (en) | 2022-01-05 | 2023-07-13 | F. Hoffmann-La Roche Ag | Derivatization of compounds in patient samples for therapeutic drug monitoring (tdm) |
| WO2023247752A1 (en) | 2022-06-23 | 2023-12-28 | F. Hoffmann-La Roche Ag | Method for diagnosing endometriosis and for classifying the stage of endometriosis |
| WO2024017982A1 (en) | 2022-07-22 | 2024-01-25 | F. Hoffmann-La Roche Ag | Leukotriene a4 hydrolase (lta4h) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome |
| WO2024017985A1 (en) | 2022-07-22 | 2024-01-25 | F. Hoffmann-La Roche Ag | Fibroblast growth factor binding protein 1 (fgfbp1) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome |
| WO2024017983A1 (en) | 2022-07-22 | 2024-01-25 | F. Hoffmann-La Roche Ag | Meteorin-like protein (metrnl) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome |
| WO2024030772A1 (en) * | 2022-08-01 | 2024-02-08 | Portland State University | High relaxivity contrast agents and stereoselective preparation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2609390A (en) * | 1950-06-01 | 1952-09-02 | Frederick C Bersworth | Phosphonic alkylene polyamino acids and method of producing same |
| US3336221A (en) * | 1964-11-05 | 1967-08-15 | Calgon Corp | Method of inhibiting precipitation and scale formation |
| US3331773A (en) * | 1966-07-22 | 1967-07-18 | Grace W R & Co | Process for inhibiting precipitation in water |
| US3434969A (en) * | 1967-08-11 | 1969-03-25 | Calgon Corp | Scale inhibiting |
| US4980148A (en) * | 1985-02-06 | 1990-12-25 | Mallinckrodt, Inc. | Methods for enhancing magnetic resonance imaging |
| US4880008A (en) * | 1985-05-08 | 1989-11-14 | The General Hospital Corporation | Vivo enhancement of NMR relaxivity |
| US4899755A (en) * | 1985-05-08 | 1990-02-13 | The General Hospital Corporation | Hepatobiliary NMR contrast agents |
| HU219485B (hu) * | 1988-06-24 | 2001-04-28 | Dow Chemical Co. | Eljárás 1,4,7,10-tetraaza-ciklododekán-származékok, ezek komplexei, valamint antitestekkel képzett konjugátumai, és ilyeneket tartalmazó gyógyszerkészítmények előállítására és a komplexeket, illetve konjugátumokat tartalmazó diagnosztikai készítmények |
| GB8914543D0 (en) * | 1989-06-23 | 1989-08-09 | Parker David | Chemical compounds |
| US5247077A (en) * | 1989-06-23 | 1993-09-21 | Celltech Limited | Tri-aza macrocycles and processes for their preparation |
| FR2672051B1 (fr) * | 1991-01-24 | 1993-05-21 | Guerbet Sa | Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique. |
| IL106159A0 (en) * | 1992-06-30 | 1993-10-20 | Dow Chemical Co | Targeted delivery of growth factors for bone regeneration |
| EP0588229A3 (en) * | 1992-09-12 | 1994-06-15 | Hoechst Ag | Macrocyclic chelating agents for the preparation of technetium or rhenium complexes |
-
1993
- 1993-05-06 US US08/057,588 patent/US5462725A/en not_active Expired - Fee Related
-
1994
- 1994-05-05 CN CN94192527.7A patent/CN1125905A/zh active Pending
- 1994-05-05 SG SG1996004873A patent/SG46458A1/en unknown
- 1994-05-05 EP EP94917922A patent/EP0711300B1/en not_active Expired - Lifetime
- 1994-05-05 AT AT94917922T patent/ATE227297T1/de not_active IP Right Cessation
- 1994-05-05 DE DE69431660T patent/DE69431660T2/de not_active Expired - Fee Related
- 1994-05-05 WO PCT/US1994/005009 patent/WO1994026275A1/en active IP Right Grant
- 1994-05-05 CZ CZ952895A patent/CZ289595A3/cs unknown
- 1994-05-05 JP JP6525558A patent/JPH08510245A/ja not_active Ceased
- 1994-05-05 AU AU69447/94A patent/AU678583B2/en not_active Ceased
- 1994-05-05 HU HU9503174A patent/HUT74565A/hu unknown
- 1994-05-05 PL PL94311643A patent/PL311643A1/xx unknown
- 1994-05-05 CA CA002162174A patent/CA2162174A1/en not_active Abandoned
-
1995
- 1995-11-06 NO NO954440A patent/NO301829B1/no unknown
- 1995-11-06 FI FI955319A patent/FI955319A/fi unknown
- 1995-12-05 BG BG100192A patent/BG100192A/xx unknown
- 1995-12-06 LV LVP-95-362A patent/LV11430B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO954440D0 (no) | 1995-11-06 |
| DE69431660D1 (de) | 2002-12-12 |
| CA2162174A1 (en) | 1994-11-24 |
| BG100192A (en) | 1996-12-31 |
| EP0711300A4 (en) | 1996-03-12 |
| NO301829B1 (no) | 1997-12-15 |
| DE69431660T2 (de) | 2003-08-21 |
| CN1125905A (zh) | 1996-07-03 |
| ATE227297T1 (de) | 2002-11-15 |
| LV11430A (lv) | 1996-08-20 |
| WO1994026275A1 (en) | 1994-11-24 |
| AU6944794A (en) | 1994-12-12 |
| AU678583B2 (en) | 1997-06-05 |
| JPH08510245A (ja) | 1996-10-29 |
| CZ289595A3 (en) | 1997-01-15 |
| NO954440L (no) | 1996-01-05 |
| US5462725A (en) | 1995-10-31 |
| HUT74565A (en) | 1997-01-28 |
| FI955319A (fi) | 1995-12-22 |
| LV11430B (en) | 1997-04-20 |
| SG46458A1 (en) | 1998-02-20 |
| HU9503174D0 (en) | 1996-01-29 |
| EP0711300B1 (en) | 2002-11-06 |
| EP0711300A1 (en) | 1996-05-15 |
| PL311643A1 (en) | 1996-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI955319A0 (fi) | 2-pyridyylimetyleenipolyatsamakrosyklofosfonihappoja, niiden komplekseja ja johdannaisia käytettäväksi vasta-aineina | |
| FI955336A (fi) | Varjoaineina käytettäviä trisyklopolyatsamakrosyklofosfonihappoja, niiden komplekseja ja johdannaisia | |
| AU2054097A (en) | Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents | |
| ES2110593T3 (es) | Acido bicicloazamacrociclofosfonico, conjugados, agentes de contraste y preparacion. | |
| DE69230970D1 (de) | Bicylclische, polyazamakrocyclocarbonsäure-komplexe, konjugate, herstellung und verwendung als kontraststoffe | |
| RU93053767A (ru) | Бициклополиазамакроциклофосфоновые кислоты, их комплексы и конъюгаты для применения в качестве контрастных агентов и способы их получения | |
| NO954442L (no) | Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler, og fremgangsmåter for deres fremstilling | |
| MY141501A (en) | Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents and processes for their preparation | |
| RU93053897A (ru) | Комплексы бициклополиазамакроциклокарбоновых кислот, их конъюгаты, фармацевтическая композиция, способ диагностики, набор и способ получения | |
| MY109649A (en) | Bicyclopol yazamacrocyclocarboxylic acid complexes, and conjugates, processes for their prepration, and use as contrast agents |